Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Post-Exposure Prophylaxis (PEP)

Update (May 23, 2018)

Interim Statement Regarding Potential Fetal Harm from Exposure to Dolutegravir – Implications for HIV Post-exposure Prophylaxis (PEP). Please see attached PDF.

Photo of a patient examining medication with doctor PEP is the use of antiretroviral drugs after a single high-risk event to stop HIV seroconversion. PEP must be started as soon as possible to be effective—and always within 72 hours of a possible exposure.

Resources for Consumers

Basic PEP Q&As – learn the basics about PEP and if it’s right for you.

PEP 101 Consumer Info Sheet (English and Spanish)

Resources for Providers

PEP Consultation Service for Clinicians

1-888-448-4911
9 a.m. – 2 a.m. ET
For more information on the services offered through the PEPline, visit the National Clinicians Consultation Center.

Guidelines

TOP